Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
18 hedge funds and large institutions have $1.73M invested in Vyant Bio, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 11 closing their positions.
257% more capital invested
Capital invested by funds: $485K → $1.73M (+$1.25M)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
22% less funds holding
Funds holding: 23 → 18 (-5)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$199K |
| 2 |
BlackRock
New York
|
+$174K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$113K |
| 4 |
LI
Leap Investments
Chicago,
Illinois
|
+$93.4K |
| 5 |
Millennium Management
New York
|
+$51.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$22K |
| 2 |
DM
Diker Management
New York
|
-$7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.83K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$4K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$4K |
VYNT Hedge Fund Activity: Q4 2019 in Review
18 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2019, worth a combined $1.73M — up 257% from $485K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VYNT and 6 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $199K. The largest seller was Geode Capital Management, exiting entirely with an estimated $22K sold.
- 18 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2019, down from 23 in Q3 2019.
- Funds reported $1.73M of Vyant Bio, Inc. Common Stock stock for Q4 2019, up 257% quarter-over-quarter.
- 6 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2019 and 11 closed out, a net change of -5 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $199K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q4 2019 was Geode Capital Management, an estimated $22K sold.
Based on aggregated 13F filings for Q4 2019.